• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

吸入疗法可降低慢性阻塞性肺疾病（COPD）的死亡率。

Inhaled therapy reduces COPD mortality.

作者信息

Andreas Stefan, Taube Christian

机构信息

University Medical Center Göttingen, Göttingen, Germany.

LungClinic Immenhausen, Immenhausen, Germany.

出版信息

ERJ Open Res. 2020 Nov 30;6(4). doi: 10.1183/23120541.00634-2020. eCollection 2020 Oct.

DOI:10.1183/23120541.00634-2020
PMID:33294425
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7701338/
Abstract

https://bit.ly/35jbEiN.

摘要

https://bit.ly/35jbEiN. （此为网址，直接保留原文形式，无法准确翻译为中文）

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4067/7701338/50f9e6748ee1/00634-2020.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4067/7701338/50f9e6748ee1/00634-2020.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4067/7701338/50f9e6748ee1/00634-2020.01.jpg

相似文献

1
Inhaled therapy reduces COPD mortality.吸入疗法可降低慢性阻塞性肺疾病（COPD）的死亡率。
ERJ Open Res. 2020 Nov 30;6(4). doi: 10.1183/23120541.00634-2020. eCollection 2020 Oct.
2
Triple therapy in COPD: understanding the data.慢性阻塞性肺疾病的三联疗法：解读相关数据。
ERJ Open Res. 2023 Jan 30;9(1). doi: 10.1183/23120541.00615-2022. eCollection 2023 Jan.
3
Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.低剂量茶碱口服联合吸入皮质激素治疗慢性阻塞性肺疾病且有加重高风险的患者：一项 RCT 研究。
Health Technol Assess. 2019 Jul;23(37):1-146. doi: 10.3310/hta23370.
4
Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.慢性阻塞性肺疾病的药物治疗：一项混合治疗比较的荟萃分析。
Pharmacotherapy. 2009 Aug;29(8):891-905. doi: 10.1592/phco.29.8.891.
5
Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease.多吸入器维持三联疗法治疗慢性阻塞性肺疾病西班牙患者时延迟起始的经济影响。
Int J Chron Obstruct Pulmon Dis. 2019 Sep 12;14:2121-2129. doi: 10.2147/COPD.S211854. eCollection 2019.
6
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.特布他林、布地奈德/福莫特罗和茚达特罗/格隆溴铵治疗慢性阻塞性肺疾病（TRIBUTE）的随机对照双盲平行分组研究
Lancet. 2018 Mar 17;391(10125):1076-1084. doi: 10.1016/S0140-6736(18)30206-X. Epub 2018 Feb 9.
7
Effectiveness and Safety Comparison for Systemic Corticosteroid Therapy With and Without Inhaled Corticosteroids for COPD Exacerbation Management.全身性皮质类固醇治疗与不联合吸入皮质类固醇治疗 COPD 加重的疗效和安全性比较。
Ann Pharmacother. 2018 Nov;52(11):1070-1077. doi: 10.1177/1060028018777769. Epub 2018 May 22.
8
Single inhaler triple therapy with extrafine beclomethasone, formoterol, and glycopyrronium for the treatment of chronic obstructive pulmonary disease.布地奈德福莫特罗格隆溴铵干粉吸入剂治疗慢性阻塞性肺疾病
Expert Opin Pharmacother. 2018 Aug;19(11):1279-1287. doi: 10.1080/14656566.2018.1498841. Epub 2018 Aug 13.
9
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.三联吸入治疗与吸入性皮质类固醇加长效β2-激动剂治疗慢性阻塞性肺疾病（TRILOGY）：一项双盲、平行组、随机对照试验。
Lancet. 2016 Sep 3;388(10048):963-73. doi: 10.1016/S0140-6736(16)31354-X. Epub 2016 Sep 1.
10
The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials.吸入性糖皮质激素对慢性阻塞性肺疾病的影响：随机安慰剂对照试验的系统评价
Am J Med. 2002 Jul;113(1):59-65. doi: 10.1016/s0002-9343(02)01143-9.

引用本文的文献

1
Delaying disease progression in COPD with early escalation to triple therapy: a modelling study (DEPICT-2).早期升级为三联疗法延缓慢性阻塞性肺疾病的疾病进展：一项建模研究（DEPICT-2）
ERJ Open Res. 2025 Apr 7;11(2). doi: 10.1183/23120541.00438-2024. eCollection 2025 Mar.
2
Effectiveness of Extrafine Single Inhaler Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) in Germany - The TriOptimize Study.德国特布他林/富马酸福莫特罗/布地奈德乌美溴铵吸入粉雾剂三联治疗慢性阻塞性肺疾病（COPD）的疗效-三优化研究。
Int J Chron Obstruct Pulmon Dis. 2022 Dec 2;17:3019-3031. doi: 10.2147/COPD.S382405. eCollection 2022.
3
ICS/Ultra LABA in the Treatment of Obstructive Airway Diseases: A Consensus of Indian Experts.

本文引用的文献

1
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.中重度至极重度 COPD 患者两种糖皮质激素剂量三联吸入治疗。
N Engl J Med. 2020 Jul 2;383(1):35-48. doi: 10.1056/NEJMoa1916046. Epub 2020 Jun 24.
2
Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病临床进展
N Engl J Med. 2019 Sep 26;381(13):1257-1266. doi: 10.1056/NEJMra1900500.
3
Decline of COPD exacerbations in clinical trials over two decades - a systematic review and meta-regression.二十多年来临床试验中 COPD 加重的减少——系统评价和荟萃回归分析。
ICS/Ultra LABA 在气道阻塞性疾病治疗中的应用：印度专家共识。
Adv Respir Med. 2022 Sep 29;90(5):407-424. doi: 10.3390/arm90050051.
4
Triple Therapy in COPD: Can We Welcome the Reduction in Cardiovascular Risk and Mortality?慢性阻塞性肺疾病的三联疗法：我们能否期待心血管风险和死亡率的降低？
Front Med (Lausanne). 2022 Mar 23;9:816843. doi: 10.3389/fmed.2022.816843. eCollection 2022.
5
Prevalence and burden of COPD misclassification in the Canadian Longitudinal Study on Aging (CLSA).COPD 在加拿大老龄化纵向研究（CLSA）中的误诊率和负担。
BMJ Open Respir Res. 2022 Mar;9(1). doi: 10.1136/bmjresp-2021-001156.
6
COPD mortality and exacerbations in the placebo group of clinical trials over two decades: a systematic review and meta-regression.二十年来临床试验安慰剂组中的慢性阻塞性肺疾病死亡率和急性加重：一项系统评价和Meta回归分析
ERJ Open Res. 2022 Mar 7;8(1). doi: 10.1183/23120541.00261-2021. eCollection 2022 Jan.
7
Beyond Dual Bronchodilation - Triple Therapy, When and Why.超越双支气管扩张 - 三联疗法，何时及为何。
Int J Chron Obstruct Pulmon Dis. 2022 Jan 14;17:165-180. doi: 10.2147/COPD.S345263. eCollection 2022.
8
Inhaled corticosteroids reduce senescence in endothelial progenitor cells from patients with COPD.吸入性皮质类固醇可减少 COPD 患者内皮祖细胞的衰老。
Thorax. 2022 Jun;77(6):616-620. doi: 10.1136/thoraxjnl-2020-216807. Epub 2022 Jan 13.
9
Overcoming Therapeutic Inertia to Reduce the Risk of COPD Exacerbations: Four Action Points for Healthcare Professionals.克服治疗惰性，降低 COPD 加重风险：医疗专业人员的四个行动要点。
Int J Chron Obstruct Pulmon Dis. 2021 Nov 1;16:3009-3016. doi: 10.2147/COPD.S329316. eCollection 2021.
10
A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink.一项在英国临床实践研究数据库中评估使用阿地氯铵和其他慢性阻塞性肺疾病药物与充血性心力衰竭住院风险相关的队列研究。
Int J Chron Obstruct Pulmon Dis. 2021 May 31;16:1461-1475. doi: 10.2147/COPD.S301624. eCollection 2021.
Respir Res. 2019 Aug 16;20(1):186. doi: 10.1186/s12931-019-1163-2.
4
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.COPD 患者每日一次单吸入器三联与双联治疗。
N Engl J Med. 2018 May 3;378(18):1671-1680. doi: 10.1056/NEJMoa1713901. Epub 2018 Apr 18.
5
Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.氟替卡松酯和维兰特罗与心血管风险升高的慢性阻塞性肺疾病患者的生存关系（SUMMIT）：一项双盲随机对照试验。
Lancet. 2016 Apr 30;387(10030):1817-26. doi: 10.1016/S0140-6736(16)30069-1. Epub 2016 Apr 28.
6
Chronic obstructive pulmonary disease and sudden cardiac death: the Rotterdam study.慢性阻塞性肺疾病与心源性猝死：鹿特丹研究。
Eur Heart J. 2015 Jul 14;36(27):1754-61. doi: 10.1093/eurheartj/ehv121. Epub 2015 Apr 28.
7
Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality.慢性阻塞性肺疾病的长期自然史：严重加重和死亡率。
Thorax. 2012 Nov;67(11):957-63. doi: 10.1136/thoraxjnl-2011-201518. Epub 2012 Jun 8.
8
A 4-year trial of tiotropium in chronic obstructive pulmonary disease.噻托溴铵用于慢性阻塞性肺疾病的4年试验。
N Engl J Med. 2008 Oct 9;359(15):1543-54. doi: 10.1056/NEJMoa0805800. Epub 2008 Oct 5.
9
Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD.吸入布地奈德对轻度慢性阻塞性肺疾病缺血性心脏事件可能具有的保护作用。
Eur Respir J. 2007 Jun;29(6):1115-9. doi: 10.1183/09031936.00128806. Epub 2007 Mar 1.
10
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.沙美特罗与丙酸氟替卡松及慢性阻塞性肺疾病患者的生存率
N Engl J Med. 2007 Feb 22;356(8):775-89. doi: 10.1056/NEJMoa063070.